Interview With The Innovators

Volume 1

Deborah Dunsire, MD, President and CEO of Millennium: The Takeda Oncology Company, and Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, discuss the issues and vision in improving personalized medicine strategies for patients with multiple myeloma.

Deborah Dunsire, MD, is the former President and CEO of Millennium Pharmaceuticals, Inc.

Volume 2

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.

Volume 3

Kim Popovits, Chairman, CEO and President, Genomic Health Inc., offers a definition of personal medicine in the first segment of this new video from Personalized Medicine in Oncology.

Volume 4

Tom Reynolds, Chief Medical Officer of Seattle Genetics, offers a definition of personal medicine in this new video series from Personalized Medicine in Oncology.

Volume 5

Michael Pellini, President and Chief Executive Officer of Foundation Medicine, offers a definition of personalized medicine in this new video series from Personalized Medicine in Oncology.

Volume 6

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Dr Lawrence Weiss, Medical Director at Clarient Diagnostic Services, discussing personalized medicine in diagnostics and with MultiOmyx™.

Volume 7

Listen as some of the top academic and community thought leaders in multiple myeloma define what precision medicine means to them.

Volume 8

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer IndexSM (BCI).

Volume 9

Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.